Heron Therapeutics Inc vs Valero Energy Corporation — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Valero Energy Corporation trades at $323.7 (market cap $90.68B). The key difference: Valero Energy Corporation is far larger — about 1430.1× Heron Therapeutics Inc's market cap, and Valero Energy Corporation pays a 1.52% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | VLO | |
|---|---|---|
Market Cap | $63.41M | $90.68B |
Sector | Health | Energy |
52-Week High | $1.49 | $323.92 |
52-Week Low | $0.32 | $133.38 |
Enterprise Value | $161.31M | $94.16B |
Dividend Yield | — | 1.52% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Valero Energy (VLO) trades at $298.31, down 1.54% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 29.31% ROE and trades at a P/E of 12.44, below industry averages. Recent news highlights geopolitical tensions supporting refining margins, while Q2 2026 earnings surged on strong refining and renewable diesel performance.
Outlook remains positive with a consensus price target of $324.27, implying 8.7% upside, but risks include volatile oil prices and declining revenue trends. Analyst sentiment is bullish with 55.55% buy ratings, though technical indicators suggest near-term caution amid bearish momentum signals.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →